Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells

被引:143
作者
Bugide, Suresh [1 ]
Green, Michael R. [2 ,3 ]
Wajapeyee, Narendra [1 ]
机构
[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[2] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA 01605 USA
[3] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA
基金
美国国家卫生研究院;
关键词
EZH2; NK cells; HCC; NK cell ligands; DNMT3A; INNATE IMMUNE RECOGNITION; NKG2D RECEPTOR; NK CELLS; EXPRESSION; LIGANDS; ACTIVATION; SORAFENIB; NIVOLUMAB; REJECTION; FAMILY;
D O I
10.1073/pnas.1802691115
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];
摘要
Natural killer (NK) cell-mediated tumor cell eradication could inhibit tumor initiation and progression. However, the factors that regulate NK cell-mediated cancer cell eradication remain unclear. We determined that hepatocellular carcinoma (HCC) cells exhibit transcriptional down-regulation of NK group 2D (NKG2D) ligands and are largely resistant to NK cell-mediated eradication. Because the down-regulation of NKG2D ligands occurred at the transcriptional level, we tested 32 chemical inhibitors of epigenetic regulators for their ability to re-express NKG2D ligands and enhance HCC cell eradication by NK cells and found that Enhancer of zeste homolog 2 (EZH2) was a transcriptional repressor of NKG2D ligands. The inhibition of EZH2 by small-molecule inhibitors or genetic means enhanced HCC cell eradication by NK cells in a NKG2D ligand-dependent manner. Collectively, these results demonstrate that EZH2 inhibition enhances HCC eradication by NK cells and that EZH2 functions, in part, as an oncogene by inhibiting immune response.
引用
收藏
页码:E3509 / E3518
页数:10
相关论文
共 37 条
[1]
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma [J].
Ally, Adrian ;
Balasundaram, Miruna ;
Carlsen, Rebecca ;
Chuah, Eric ;
Clarke, Amanda ;
Dhalla, Noreen ;
Holt, Robert A. ;
Jones, Steven J. M. ;
Lee, Darlene ;
Ma, Yussanne ;
Marra, Marco A. ;
Mayo, Michael ;
Moore, Richard A. ;
Mungall, Andrew J. ;
Schein, Jacqueline E. ;
Sipahimalani, Payal ;
Tam, Angela ;
Thiessen, Nina ;
Cheung, Dorothy ;
Wong, Tina ;
Brooks, Denise ;
Robertson, A. Gordon ;
Bowlby, Reanne ;
Mungall, Karen ;
Sadeghi, Sara ;
Xi, Liu ;
Covington, Kyle ;
Shinbrot, Eve ;
Wheeler, David A. ;
Gibbs, Richard A. ;
Donehower, Lawrence A. ;
Wang, Linghua ;
Bowen, Jay ;
Gastier-Foster, Julie M. ;
Gerken, Mark ;
Helsel, Carmen ;
Leraas, Kristen M. ;
Lichtenberg, Tara M. ;
Ramirez, Nilsa C. ;
Wise, Lisa ;
Zmuda, Erik ;
Gabriel, Stacey B. ;
Meyerson, Matthew ;
Cibulskis, Carrie ;
Murray, Bradley A. ;
Shih, Juliann ;
Beroukhim, Rameen ;
Cherniack, Andrew D. ;
Schumacher, Steven E. ;
Saksena, Gordon .
CELL, 2017, 169 (07) :1327-+
[2]
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].
Ansell, Stephen M. ;
Lesokhin, Alexander M. ;
Borrello, Ivan ;
Halwani, Ahmad ;
Scott, Emma C. ;
Gutierrez, Martin ;
Schuster, Stephen J. ;
Millenson, Michael M. ;
Cattry, Deepika ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Chapuy, Bjoern ;
Ligon, Azra H. ;
Zhu, Lili ;
Grosso, Joseph F. ;
Kim, Su Young ;
Timmerman, John M. ;
Shipp, Margaret A. ;
Armand, Philippe .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319
[3]
Activation of NK Cells and T Cells by NKG2D, a Receptor for Stress-Inducible MICA [J].
Bauer, Stefan ;
Groh, Veronika ;
Wu, Jun ;
Steinle, Alexander ;
Phillips, Joseph H. ;
Lanier, Lewis L. ;
Spies, Thomas .
JOURNAL OF IMMUNOLOGY, 2018, 200 (07) :2231-2233
[4]
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Bruix, Jordi ;
Qin, Shukui ;
Merle, Philippe ;
Granito, Alessandro ;
Huang, Yi-Hsiang ;
Bodoky, Gyrogy ;
Pracht, Marc ;
Yokosuka, Osamu ;
Rosmorduc, Olivier ;
Breder, Valeriy ;
Gerolami, Rene ;
Masi, Gianluca ;
Ross, Paul J. ;
Song, Tianqiang ;
Bronowicki, Jean-Pierre ;
Ollivier-Hourmand, Isabelle ;
Kudo, Masatoshi ;
Cheng, Ann-Lii ;
Llovet, Josep M. ;
Finn, Richard S. ;
LeBerre, Marie-Aude ;
Baumhauer, Annette ;
Meinhardt, Gerold ;
Han, Guohong .
LANCET, 2017, 389 (10064) :56-66
[5]
ANATOMY OF PAROTOID GLAND IN BUFONIDAE WITH SOME HISTOCHEMICAL FINDINGS .2. BUFO-ALVARIUS [J].
CANNON, MS ;
HOSTETLER, JR .
JOURNAL OF MORPHOLOGY, 1976, 148 (02) :137-159
[6]
Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice [J].
Cerwenka, A ;
Bakker, ABH ;
McClanahan, T ;
Wagner, J ;
Wu, J ;
Phillips, JH ;
Lanier, LL .
IMMUNITY, 2000, 12 (06) :721-727
[7]
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo [J].
Cerwenka, A ;
Baron, JL ;
Lanier, LL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11521-11526
[8]
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses [J].
Chiappinelli, Katherine B. ;
Strissel, Pamela L. ;
Desrichard, Alexis ;
Li, Huili ;
Henke, Christine ;
Akman, Benjamin ;
Hein, Alexander ;
Rote, Neal S. ;
Cope, Leslie M. ;
Snyder, Alexandra ;
Makarov, Vladimir ;
Buhu, Sadna ;
Slamon, Dennis J. ;
Wolchok, Jedd D. ;
Pardoll, Drew M. ;
Beckmann, Matthias W. ;
Zahnow, Cynthia A. ;
Mergoub, Taha ;
Chan, Timothy A. ;
Baylin, Stephen B. ;
Strick, Reiner .
CELL, 2015, 162 (05) :974-986
[9]
Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages [J].
Diefenbach, A ;
Jamieson, AM ;
Liu, SD ;
Shastri, N ;
Raulet, DH .
NATURE IMMUNOLOGY, 2000, 1 (02) :119-126
[10]
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity [J].
Diefenbach, A ;
Jensen, ER ;
Jamieson, AM ;
Raulet, DH .
NATURE, 2001, 413 (6852) :165-171